# Marjolein de Bruin‐Weller

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/marjolein-de-bruin-weller/

## Facts

| Field | Value |
| --- | --- |
| Citations | 14,269 |
| Field | Dermatology and Skin Diseases |
| h-index | 56 |
| i10-index | 173 |
| Last Known Institution | Utrecht University |
| OpenAlex ID | https://openalex.org/A5013549423 |
| ORCID iD | 0000-0002-1249-6993 |
| Works | 364 |

## Researcher papers

- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Epidemiology of atopic dermatitis in adults: Results from an international survey](https://scholariq.org/papers/epidemiology-of-atopic-dermatitis-in-adults-results-from-an-international-survey/)
- [Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-upadacitinib-vs-dupilumab-in-adults-with-moderate-to/)
- [Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t](https://scholariq.org/papers/dupilumab-with-concomitant-topical-corticosteroid-treatment-in-adults-with/)
- [ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children](https://scholariq.org/papers/etfad-eadv-eczema-task-force-2020-position-paper-on-diagnosis-and-treatment-of/)
- [Conjunctivitis in dupilumab clinical trials](https://scholariq.org/papers/conjunctivitis-in-dupilumab-clinical-trials/)
- [Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/safety-and-efficacy-of-upadacitinib-in-combination-with-topical-corticosteroids/)
- [ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients](https://scholariq.org/papers/etfad-eadv-eczema-task-force-2015-position-paper-on-diagnosis-and-treatment-of/)
- [Anti‐IL‐5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis](https://scholariq.org/papers/anti-il-5-recombinant-humanized-monoclonal-antibody-mepolizumab-for-the/)
- [Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell–attracting chemokine (CTACK) levels in allergic diseases](https://scholariq.org/papers/serum-thymus-and-activation-regulated-chemokine-tarc-and-cutaneous-t-cell/)
- [Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment](https://scholariq.org/papers/economic-burden-of-adult-patients-with-moderate-to-severe-atopic-dermatitis/)
- [Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry](https://scholariq.org/papers/rapid-and-sustained-effect-of-dupilumab-on-work-productivity-in-patients-with/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions/)

## Researcher university

- [Utrecht University](https://scholariq.org/institutions/utrecht-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.